Conclusion
Here, we present a case of disseminated aspergillus infection in the
setting of zanubrutinib use in a patient with marginal zone lymphoma.
His clinical course was likely impacted by a prolonged steroid course
which resulted in dysfunction of his innate immune system and
neutropenia in the setting of BTKi administration. Due to the limited
time that this medication has been on the market and the limited number
of published cases pertaining to adverse events, it is difficult to
assess whether or not the greater propensity of neutropenia in
zanubrutinib increases the likelihood of fungal infection. Zanubrutinib
may also play a role in decreased neutrophil function in the remaining
cells present. We expect that there will be greater understanding as
additional cases are presented.